Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1285
https://www.valueinhealthjournal.com/article/S1098-3015(16)32651-1/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1210
First Page :
A569
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32651-1&doi=10.1016/j.jval.2016.09.1285